Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 7th:
Sibanye Gold Limited : This precious metals mining company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.9% over the last 60 days.
Sibanye Gold Limited Price and Consensus
Sibanye Gold’s shares gained 7.9% over the last one month more than S&P 500’s loss of -3.8%. The company possesses a Momentum Score of B.
Sibanye Gold Limited Price
COUPA SOFTWARE : This is a cloud-based spend management platform provider has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days.
COUPA SOFTWARE Price and Consensus
COUPA’s shares gained 4.9% over the last one month. The company possesses a Momentum Score of B.
COUPA SOFTWARE Price
The Buckle Inc. (BKE - Free Report) : This apparel, footwear and accessories retailer has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.5% over the last 60 days.
Buckle, Inc. (The) Price and Consensus
The Buckle’s shares gained 5.7% over the last one month. The company possesses a Momentum Score of A.
Buckle, Inc. (The) Price
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 7th:
Sibanye Gold Limited : This precious metals mining company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.9% over the last 60 days.
Sibanye Gold Limited Price and Consensus
Sibanye Gold’s shares gained 7.9% over the last one month more than S&P 500’s loss of -3.8%. The company possesses a Momentum Score of B.
Sibanye Gold Limited Price
COUPA SOFTWARE : This is a cloud-based spend management platform provider has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days.
COUPA SOFTWARE Price and Consensus
COUPA’s shares gained 4.9% over the last one month. The company possesses a Momentum Score of B.
COUPA SOFTWARE Price
The Buckle Inc. (BKE - Free Report) : This apparel, footwear and accessories retailer has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.5% over the last 60 days.
Buckle, Inc. (The) Price and Consensus
The Buckle’s shares gained 5.7% over the last one month. The company possesses a Momentum Score of A.
Buckle, Inc. (The) Price
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BKE - FREE